Diabetes Mellitus Flashcards
T1DM clinical features
Adolescent onset usually but may occur at any age e.g. latent autoimmune diabetes of adults
Insulin deficiency from beta-cell autoimmune destruction
Associated with other autoimmune disorders
Prone to ketoacidosis + weight loss
T2DM clinical features
Higher prevalence in old, Asian men
Less insulin secretion ± increased insulin resistance
Stronger genetic influence than T1DM
Associated with sedentary, obese, alcohol excess
MODY is a rare autosomal dominant form of T2DM
Impaired glucose tolerance definition
Fasting plasma glucose <7mmol/L and
OGTT 2h glucose ≥7.8mmol/L but <11.1mmol/L
Impaired fasting glucose definition
Fasting plasma glucose ≥6.1 but <7mmol/L
OGTT more normal
Causes of DM
Steroids, anti-HIV drugs, newer antipsychotics
Pancreas damage (including haemochromatosis + CF)
Cushing’s disease, acromegaly, phaeochromocytoma, hyperthydroidism, pregnancy
Congenital lipodystrophy
Glycogen storage disease
Metabolic syndrome definition
Central obesity (BMI>30 or inc waist circumference) and two from:
BP≥130/85
Triglycerides ≥1.7mmol/L
HDL ≤1.03(men)/1.29(women)
Fasting glucose ≥5.6
T2DM
DM diagnosis criteria
Hyperglycaemia symptoms + raised glucose once (fasting ≥7, random ≥11.1)
Raised venous glucose twice (fasting ≥7, random ≥11.1)
OGTT 2h value ≥11.1
HBA1C ≥48
Hyperglycaemia symptoms
Polyuria Polydipsia Unexplained weight loss Visual blurring Genital thrush Lethargy
DM general management
Healthy eating Assess vascular risk + statin Review HBA1C every 6mths Foot/eye care Pt inform DVLA and not drive if hypoglycaemic spells
T2DM pharm management stages
Lifestyle
Metformin monotherapy
HBA1C rises to 58, add DPP-4 inhibitor/ pioglitazone/ sulphonylurea (SU) / SGLT-2I (glifazon)
HBA1C still 58 then add SU to DPP4/pio or SGLT-2I to SU/pio, add insulin at this stage if necessary
Add GLP-1 analogues (exenatide, liraglitide) if still not responding and pt not suitable for insulin (e.g. BMI>35)
Metformin MOA
Increase insulin sensitivity + helps weight
DPP4 inhibitor (gliptins) MOA
Block DPP-4 action which destroys incretin
Glitazone MOA
Increases insulin sensitivity
Metformin CI
eGFR ≤36 due to lactic acidosis risk
Glitazone CI
CCF past or present due to fluid retention SE
Osteoporosis
Stop if increased weight/oedema
Sulphonylurea MOA
Increase insulin secretion
SGLT-2I MOA
E.g. empagliflozin
Selective sodium-glucose co-transporter 2 inhibitor blocks glucose reabsorption in kidneys so excreted in urine
Subcut insulin types
Ultra-fast before meals (humalog, novorapid)
Isophane (peak at 4-12h)
Pre-mixed (e.g. Novomix 30 (30% short, 70% long acting)
Long-acting e.g. glargine before bed, detemir in overweight T2DM
Insulin during illness
Don’t stop taking, illness often increases insulin requirement despite reduced food intake